ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $35.82 Consensus Target Price from Brokerages

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen research firms that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 […]

Related Keywords

Canada ,United States ,Alger ,Algeria ,James Kihara ,Robertw Baird ,Stephen Davis ,Pharmaceuticals Daily ,Norges Bank ,Needham Company ,Pharmaceuticals Inc ,Nasdaq ,Fred Alger Management ,Mg Investment Management Ltd ,Pharmaceuticals Price Performance ,Royal Bank ,Eventide Asset Management ,Get Free Report ,Marketbeat Ratings ,Alger Management ,Asset Management ,Get Free ,Acadia Pharmaceuticals ,Nasdaq Acad ,Facad ,Medical ,Ratings ,Consensus ,